{
    "abstract": "In the United States, herpes zoster (HZ) and related complications are estimated to result in approximately $1.3 billion in medical care costs and $1.7 billion in indirect costs annually. In this study, we compared the cost-effectiveness of a new Adjuvanted Recombinant Zoster Vaccine (RZV), containing recombinant varicella-zoster virus glycoprotein E and the AS01B Adjuvant System, versus No Vaccine, as well as versus the live attenuated HZ vaccine (Zoster Vaccine Live (ZVL)) in subjects aged 60+ years of age (YOA) and other age cohorts aged 50+ YOA. A multi-cohort Markov model was developed which follows 1 million individuals over their remaining lifetimes from the year of vaccination with annual cycle lengths. Second dose compliance for RZV was assumed to be 69%. Efficacy and waning parameters were derived from clinical trials for both vaccines. Epidemiological parameters, costs and utility model inputs were derived from US-specific population-based data. Costs and outcomes were discounted at 3% per year. Deterministic and probabilistic sensitivity analysis, along with scenario and threshold analysis were carried out to explore the overall uncertainty in the model. The model estimated that, compared to No Vaccine against HZ, RZV would prevent 103,603 HZ cases, 11,197 postherpetic neuralgia (PHN) cases, and 14,455 other complications, at an incremental cost of $11,863 per quality-adjusted life-year saved from a societal perspective. Compared to ZVL, the model estimated that, RZV would prevent 71,638 additional HZ cases, 6403 PHN cases, and over 10,582 other complications, resulting in net total societal cost savings of over $96 million. The results were robust to a wide range of sensitivity analyses. Vaccination against HZ with RZV is cost-effective compared to No Vaccine and cost-saving compared to ZVL, in the US population aged 60+ YOA. Clinicaltrial.gov. registered#: NA.",
    "author_highlights": [
        {
            "endOffset": 17633,
            "sentence": "In the United States, Herpes Zoster results in $1.3 billion in medical care costs annually.",
            "startOffset": 17542
        },
        {
            "endOffset": 17731,
            "sentence": "This burden is projected to rise substantially over the coming years due to the aging population.",
            "startOffset": 17634
        },
        {
            "endOffset": 17830,
            "sentence": "We compare a new Recombinant Zoster Vaccine (RZV) versus Zoster Vaccine Live (ZVL) and No Vaccine.",
            "startOffset": 17732
        },
        {
            "endOffset": 17924,
            "sentence": "RZV is cost-effective compared to no vaccination and cost-saving compared to ZVL vaccination.",
            "startOffset": 17831
        },
        {
            "endOffset": 17995,
            "sentence": "Results were robust to a variety of sensitivity and scenario analyses.",
            "startOffset": 17925
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Michael N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                }
            ],
            "firstpage": "S13",
            "issn": "00986151",
            "lastpage": "S17",
            "pmid": "19553630",
            "pub_year": 2009,
            "title": "Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence",
            "volume": "109"
        },
        "b0010": {
            "authors": [
                {
                    "first": "David W.",
                    "initial": "D.W.",
                    "last": "Kimberlin"
                },
                {
                    "first": "Richard J.",
                    "initial": "R.J.",
                    "last": "Whitley"
                }
            ],
            "doi": "10.1056/NEJMct066061",
            "firstpage": "1338",
            "issn": "00284793",
            "lastpage": "1343",
            "pmid": "17392303",
            "pub_year": 2007,
            "title": "Varicella-zoster vaccine for the prevention of herpes zoster",
            "volume": "356"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Kosuke",
                    "initial": "K.",
                    "last": "Kawai"
                },
                {
                    "first": "Emmanuelle",
                    "initial": "E.",
                    "last": "Preaud"
                },
                {
                    "first": "Florence",
                    "initial": "F.",
                    "last": "Baron-Papillon"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Largeron"
                },
                {
                    "first": "Camilo J.",
                    "initial": "C.J.",
                    "last": "Acosta"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.01.058",
            "firstpage": "1645",
            "issn": "0264410X",
            "lastpage": "1653",
            "pmid": "24534737",
            "pub_year": 2014,
            "title": "Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: A critical review",
            "volume": "32"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Niklaus H.",
                    "initial": "N.H.",
                    "last": "Mueller"
                },
                {
                    "first": "Donald H.",
                    "initial": "D.H.",
                    "last": "Gilden"
                },
                {
                    "first": "Randall J.",
                    "initial": "R.J.",
                    "last": "Cohrs"
                },
                {
                    "first": "Ravi",
                    "initial": "R.",
                    "last": "Mahalingam"
                },
                {
                    "first": "Maria A.",
                    "initial": "M.A.",
                    "last": "Nagel"
                }
            ],
            "doi": "10.1016/j.ncl.2008.03.011",
            "firstpage": "675",
            "issn": "07338619",
            "lastpage": "697",
            "pmid": "18657721",
            "pub_year": 2008,
            "title": "Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis of Disease, and Latency",
            "volume": "26"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Robert H.",
                    "initial": "R.H.",
                    "last": "Dworkin"
                },
                {
                    "first": "Robert W.",
                    "initial": "R.W.",
                    "last": "Johnson"
                },
                {
                    "first": "Judith",
                    "initial": "J.",
                    "last": "Breuer"
                },
                {
                    "first": "John W.",
                    "initial": "J.W.",
                    "last": "Gnann"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Miroslav",
                    "initial": "M.",
                    "last": "Backonja"
                },
                {
                    "first": "Robert F.",
                    "initial": "R.F.",
                    "last": "Betts"
                },
                {
                    "first": "Anne A.",
                    "initial": "A.A.",
                    "last": "Gershon"
                },
                {
                    "first": "Maija L.",
                    "initial": "M.L.",
                    "last": "Haanp\u00e4\u00e4"
                },
                {
                    "first": "Michael W.",
                    "initial": "M.W.",
                    "last": "McKendrick"
                },
                {
                    "first": "Turo J.",
                    "initial": "T.J.",
                    "last": "Nurmikko"
                },
                {
                    "first": "Anne Louise",
                    "initial": "A.L.",
                    "last": "Oaklander"
                },
                {
                    "first": "Michael N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                },
                {
                    "first": "Deborah",
                    "initial": "D.",
                    "last": "Pavan-Langston"
                },
                {
                    "first": "Karin L.",
                    "initial": "K.L.",
                    "last": "Petersen"
                },
                {
                    "first": "Michael C.",
                    "initial": "M.C.",
                    "last": "Rowbotham"
                },
                {
                    "first": "Kenneth E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "Brett R.",
                    "initial": "B.R.",
                    "last": "Stacey"
                },
                {
                    "first": "Stephen K.",
                    "initial": "S.K.",
                    "last": "Tyring"
                },
                {
                    "first": "Albert J.M.",
                    "initial": "A.J.M.",
                    "last": "Van Wijck"
                },
                {
                    "first": "Mark S.",
                    "initial": "M.S.",
                    "last": "Wallace"
                },
                {
                    "first": "Sawko W.",
                    "initial": "S.W.",
                    "last": "Wassilew"
                },
                {
                    "first": "Richard J.",
                    "initial": "R.J.",
                    "last": "Whitley"
                }
            ],
            "doi": "10.1086/510206",
            "firstpage": "S1",
            "issn": "10584838",
            "lastpage": "S26",
            "pmid": "17143845",
            "pub_year": 2007,
            "title": "Recommendations for the management of herpes zoster",
            "volume": "44"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Barbara P.",
                    "initial": "B.P.",
                    "last": "Yawn"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Saddier"
                },
                {
                    "first": "Peter C.",
                    "initial": "P.C.",
                    "last": "Wollan"
                },
                {
                    "first": "Jennifer L.",
                    "initial": "J.L.",
                    "last": "St. Sauver"
                },
                {
                    "first": "Marge J.",
                    "initial": "M.J.",
                    "last": "Kurland"
                },
                {
                    "first": "Lina S.",
                    "initial": "L.S.",
                    "last": "Sy"
                }
            ],
            "doi": "10.4065/82.11.1341",
            "firstpage": "1341",
            "issn": "00256196",
            "lastpage": "1349",
            "pub_year": 2007,
            "title": "A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction",
            "volume": "82"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Gerry",
                    "initial": "G.",
                    "last": "Oster"
                },
                {
                    "first": "Gale",
                    "initial": "G.",
                    "last": "Harding"
                },
                {
                    "first": "Ellen",
                    "initial": "E.",
                    "last": "Dukes"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Edelsberg"
                },
                {
                    "first": "Paul D.",
                    "initial": "P.D.",
                    "last": "Cleary"
                }
            ],
            "doi": "10.1016/j.jpain.2005.01.359",
            "firstpage": "356",
            "issn": "15265900",
            "lastpage": "363",
            "pmid": "15943957",
            "pub_year": 2005,
            "title": "Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: Results from a population-based survey",
            "volume": "6"
        },
        "b0040": {
            "authors": [
                {
                    "first": "M\u00e9lanie",
                    "initial": "M.",
                    "last": "Drolet"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Brisson"
                },
                {
                    "first": "Kenneth E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Johnson"
                },
                {
                    "first": "Michael N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Patrick"
                },
                {
                    "first": "Caty",
                    "initial": "C.",
                    "last": "Blanchette"
                },
                {
                    "first": "James A.",
                    "initial": "J.A.",
                    "last": "Mansi"
                }
            ],
            "doi": "10.1503/cmaj.091711",
            "firstpage": "1731",
            "issn": "08203946",
            "lastpage": "1736",
            "pub_year": 2010,
            "title": "The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: A prospective study",
            "volume": "182"
        },
        "b0045": null,
        "b0050": {
            "authors": [
                {
                    "first": "John M.",
                    "initial": "J.M.",
                    "last": "McLaughlin"
                },
                {
                    "first": "Justin J.",
                    "initial": "J.J.",
                    "last": "McGinnis"
                },
                {
                    "first": "Litjen",
                    "initial": "L.",
                    "last": "Tan"
                },
                {
                    "first": "Annette",
                    "initial": "A.",
                    "last": "Mercatante"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Fortuna"
                }
            ],
            "doi": "10.1007/s10935-015-0394-3",
            "firstpage": "259",
            "issn": "0278095X",
            "lastpage": "273",
            "pmid": "26032932",
            "pub_year": 2015,
            "title": "Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013",
            "volume": "36"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Lijoy",
                    "initial": "L.",
                    "last": "Varghese"
                },
                {
                    "first": "Baudouin",
                    "initial": "B.",
                    "last": "Standaert"
                },
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Olivieri"
                },
                {
                    "first": "Desmond",
                    "initial": "D.",
                    "last": "Curran"
                }
            ],
            "doi": "10.1186/s12877-017-0420-9",
            "firstpage": "1",
            "issn": "14712318",
            "lastpage": "7",
            "pmid": "28114907",
            "pub_year": 2017,
            "title": "The temporal impact of aging on the burden of herpes zoster",
            "volume": "17"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Harpaz"
                },
                {
                    "first": "Ismael R.",
                    "initial": "I.R.",
                    "last": "Ortega-Sanchez"
                },
                {
                    "first": "Jane F.",
                    "initial": "J.F.",
                    "last": "Seward"
                }
            ],
            "firstpage": "1",
            "issn": "15458601",
            "lastpage": "CE2",
            "pmid": "18528318",
            "pub_year": 2008,
            "title": "Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).",
            "volume": "57"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Craig M.",
                    "initial": "C.M.",
                    "last": "Hales"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Harpaz"
                },
                {
                    "first": "Ismael",
                    "initial": "I.",
                    "last": "Ortega-Sanchez"
                },
                {
                    "first": "Stephanie R.",
                    "initial": "S.R.",
                    "last": "Bialek"
                }
            ],
            "firstpage": "729",
            "issn": "01492195",
            "lastpage": "731",
            "pmid": "25144544",
            "pub_year": 2014,
            "title": "Update on recommendations for use of herpes zoster vaccine",
            "volume": "63"
        },
        "b0070": null,
        "b0075": {
            "authors": [
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "Anthony L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Diez-Domingo"
                },
                {
                    "first": "Shinn Jang",
                    "initial": "S.J.",
                    "last": "Hwang"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Janet E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "Airi",
                    "initial": "A.",
                    "last": "Poder"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Puig-Barber\u00e0"
                },
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Daisuke",
                    "initial": "D.",
                    "last": "Watanabe"
                },
                {
                    "first": "Lily",
                    "initial": "L.",
                    "last": "Weckx"
                },
                {
                    "first": "Toufik",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1056/NEJMoa1501184",
            "firstpage": "2087",
            "issn": "00284793",
            "lastpage": "2096",
            "pmid": "25916341",
            "pub_year": 2015,
            "title": "Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults",
            "volume": "372"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Kenneth E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "John W.",
                    "initial": "J.W.",
                    "last": "Gnann"
                },
                {
                    "first": "Shelly A.",
                    "initial": "S.A.",
                    "last": "McNeil"
                },
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Robert F.",
                    "initial": "R.F.",
                    "last": "Betts"
                },
                {
                    "first": "Susan",
                    "initial": "S.",
                    "last": "Keay"
                },
                {
                    "first": "Jon E.",
                    "initial": "J.E.",
                    "last": "Stek"
                },
                {
                    "first": "Nickoya D.",
                    "initial": "N.D.",
                    "last": "Bundick"
                },
                {
                    "first": "Shu Chih",
                    "initial": "S.C.",
                    "last": "Su"
                },
                {
                    "first": "Yanli",
                    "initial": "Y.",
                    "last": "Zhao"
                },
                {
                    "first": "Xiaoming",
                    "initial": "X.",
                    "last": "Li"
                },
                {
                    "first": "Ivan S.F.",
                    "initial": "I.S.F.",
                    "last": "Chan"
                },
                {
                    "first": "Paula W.",
                    "initial": "P.W.",
                    "last": "Annunziato"
                },
                {
                    "first": "Janie",
                    "initial": "J.",
                    "last": "Parrino"
                }
            ],
            "doi": "10.1093/cid/cir970",
            "firstpage": "922",
            "issn": "10584838",
            "lastpage": "928",
            "pmid": "22291101",
            "pub_year": 2012,
            "title": "Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years",
            "volume": "54"
        },
        "b0085": {
            "authors": [
                {
                    "first": "A. L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Kovac"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "S. J.",
                    "initial": "S.J.",
                    "last": "Hwang"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "D\u00edez-Domingo"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Puig-Barber\u00e0"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Vanden Abeele"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Watanabe"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Ahonen"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Athan"
                },
                {
                    "first": "J. F.",
                    "initial": "J.F.",
                    "last": "Barba-Gomez"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Campora"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "De Looze"
                },
                {
                    "first": "H. J.",
                    "initial": "H.J.",
                    "last": "Downey"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Ghesquiere"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Gorfinkel"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Korhonen"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Leung"
                },
                {
                    "first": "S. A.",
                    "initial": "S.A.",
                    "last": "McNeil"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Oostvogels"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Rombo"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Smetana"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Weckx"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Yeo"
                },
                {
                    "first": "T. C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.1056/NEJMoa1603800",
            "firstpage": "1019",
            "issn": "00284793",
            "lastpage": "1032",
            "pmid": "27626517",
            "pub_year": 2016,
            "title": "Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older",
            "volume": "375"
        },
        "b0090": null,
        "b0095": {
            "authors": [
                {
                    "first": "Kathleen L.",
                    "initial": "K.L.",
                    "last": "Dooling"
                },
                {
                    "first": "Angela",
                    "initial": "A.",
                    "last": "Guo"
                },
                {
                    "first": "Manisha",
                    "initial": "M.",
                    "last": "Patel"
                },
                {
                    "first": "Grace M.",
                    "initial": "G.M.",
                    "last": "Lee"
                },
                {
                    "first": "Kelly",
                    "initial": "K.",
                    "last": "Moore"
                },
                {
                    "first": "Edward A.",
                    "initial": "E.A.",
                    "last": "Belongia"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Harpaz"
                }
            ],
            "doi": "10.15585/mmwr.mm6703a5",
            "firstpage": "103",
            "issn": "01492195",
            "lastpage": "108",
            "pmid": "29370152",
            "pub_year": 2018,
            "title": "Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines",
            "volume": "67"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Desmond",
                    "initial": "D.",
                    "last": "Curran"
                },
                {
                    "first": "Desir\u00e9e",
                    "initial": "D.",
                    "last": "Van Oorschot"
                },
                {
                    "first": "Lijoy",
                    "initial": "L.",
                    "last": "Varghese"
                },
                {
                    "first": "Lidia",
                    "initial": "L.",
                    "last": "Oostvogels"
                },
                {
                    "first": "Tomas",
                    "initial": "T.",
                    "last": "Mrkvan"
                },
                {
                    "first": "Romulo",
                    "initial": "R.",
                    "last": "Colindres"
                },
                {
                    "first": "Alfred",
                    "initial": "A.",
                    "last": "von Krempelhuber"
                },
                {
                    "first": "Anastassia",
                    "initial": "A.",
                    "last": "Anastassopoulou"
                }
            ],
            "doi": "10.1080/21645515.2017.1345399",
            "firstpage": "2213",
            "issn": "21645515",
            "lastpage": "2221",
            "pmid": "28708959",
            "pub_year": 2017,
            "title": "Assessment of the potential public health impact of Herpes Zoster vaccination in Germany",
            "volume": "13"
        },
        "b0105": null,
        "b0110": null,
        "b0115": {
            "authors": [
                {
                    "first": "M. N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "G. R.",
                    "initial": "G.R.",
                    "last": "Johnson"
                },
                {
                    "first": "K. E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "S. E.",
                    "initial": "S.E.",
                    "last": "Straus"
                },
                {
                    "first": "L. D.",
                    "initial": "L.D.",
                    "last": "Gelb"
                },
                {
                    "first": "R. D.",
                    "initial": "R.D.",
                    "last": "Arbeit"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Simberkoff"
                },
                {
                    "first": "A. A.",
                    "initial": "A.A.",
                    "last": "Gershon"
                },
                {
                    "first": "L. E.",
                    "initial": "L.E.",
                    "last": "Davis"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Weinberg"
                },
                {
                    "first": "K. D.",
                    "initial": "K.D.",
                    "last": "Boardman"
                },
                {
                    "first": "H. M.",
                    "initial": "H.M.",
                    "last": "Williams"
                },
                {
                    "first": "J. Hongyuan",
                    "initial": "J.H.",
                    "last": "Zhang"
                },
                {
                    "first": "P. N.",
                    "initial": "P.N.",
                    "last": "Peduzzi"
                },
                {
                    "first": "C. E.",
                    "initial": "C.E.",
                    "last": "Beisel"
                },
                {
                    "first": "V. A.",
                    "initial": "V.A.",
                    "last": "Morrison"
                },
                {
                    "first": "J. C.",
                    "initial": "J.C.",
                    "last": "Guatelli"
                },
                {
                    "first": "P. A.",
                    "initial": "P.A.",
                    "last": "Brooks"
                },
                {
                    "first": "C. A.",
                    "initial": "C.A.",
                    "last": "Kauffman"
                },
                {
                    "first": "C. T.",
                    "initial": "C.T.",
                    "last": "Pachucki"
                },
                {
                    "first": "K. M.",
                    "initial": "K.M.",
                    "last": "Neuzil"
                },
                {
                    "first": "R. F.",
                    "initial": "R.F.",
                    "last": "Betts"
                },
                {
                    "first": "P. F.",
                    "initial": "P.F.",
                    "last": "Wright"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Griffin"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Brunell"
                },
                {
                    "first": "N. E.",
                    "initial": "N.E.",
                    "last": "Soto"
                },
                {
                    "first": "A. R.",
                    "initial": "A.R.",
                    "last": "Marques"
                },
                {
                    "first": "S. K.",
                    "initial": "S.K.",
                    "last": "Keay"
                },
                {
                    "first": "R. P.",
                    "initial": "R.P.",
                    "last": "Goodman"
                },
                {
                    "first": "D. J.",
                    "initial": "D.J.",
                    "last": "Cotton"
                },
                {
                    "first": "J. W.",
                    "initial": "J.W.",
                    "last": "Gnann"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Loutit"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Holodniy"
                },
                {
                    "first": "W. A.",
                    "initial": "W.A.",
                    "last": "Keitel"
                },
                {
                    "first": "G. E.",
                    "initial": "G.E.",
                    "last": "Crawford"
                },
                {
                    "first": "S. S.",
                    "initial": "S.S.",
                    "last": "Yeh"
                },
                {
                    "first": "Z.",
                    "initial": "Z.",
                    "last": "Lobo"
                },
                {
                    "first": "J. F.",
                    "initial": "J.F.",
                    "last": "Toney"
                },
                {
                    "first": "R. N.",
                    "initial": "R.N.",
                    "last": "Greenberg"
                },
                {
                    "first": "P. M.",
                    "initial": "P.M.",
                    "last": "Keller"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Harbecke"
                },
                {
                    "first": "A. R.",
                    "initial": "A.R.",
                    "last": "Hayward"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Irwin"
                },
                {
                    "first": "T. C.",
                    "initial": "T.C.",
                    "last": "Kyriakides"
                },
                {
                    "first": "C. Y.",
                    "initial": "C.Y.",
                    "last": "Chan"
                },
                {
                    "first": "I. S.F.",
                    "initial": "I.S.F.",
                    "last": "Chan"
                },
                {
                    "first": "W. W.B.",
                    "initial": "W.W.B.",
                    "last": "Wang"
                },
                {
                    "first": "P. W.",
                    "initial": "P.W.",
                    "last": "Annunziato"
                },
                {
                    "first": "J. L.",
                    "initial": "J.L.",
                    "last": "Silber"
                }
            ],
            "doi": "10.1056/NEJMoa051016",
            "firstpage": "2271",
            "issn": "00284793",
            "lastpage": "2365",
            "pmid": "15930418",
            "pub_year": 2005,
            "title": "A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults",
            "volume": "352"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Vicki A.",
                    "initial": "V.A.",
                    "last": "Morrison"
                },
                {
                    "first": "Gary R.",
                    "initial": "G.R.",
                    "last": "Johnson"
                },
                {
                    "first": "Kenneth E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Jane H.",
                    "initial": "J.H.",
                    "last": "Zhang"
                },
                {
                    "first": "David J.",
                    "initial": "D.J.",
                    "last": "Looney"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Betts"
                },
                {
                    "first": "Larry",
                    "initial": "L.",
                    "last": "Gelb"
                },
                {
                    "first": "John C.",
                    "initial": "J.C.",
                    "last": "Guatelli"
                },
                {
                    "first": "Ruth",
                    "initial": "R.",
                    "last": "Harbecke"
                },
                {
                    "first": "Connie",
                    "initial": "C.",
                    "last": "Pachucki"
                },
                {
                    "first": "Susan",
                    "initial": "S.",
                    "last": "Keay"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Menzies"
                },
                {
                    "first": "Marie R.",
                    "initial": "M.R.",
                    "last": "Griffin"
                },
                {
                    "first": "Carol A.",
                    "initial": "C.A.",
                    "last": "Kauffman"
                },
                {
                    "first": "Adriana",
                    "initial": "A.",
                    "last": "Marques"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Toney"
                },
                {
                    "first": "Kathy",
                    "initial": "K.",
                    "last": "Boardman"
                },
                {
                    "first": "Shu Chih",
                    "initial": "S.C.",
                    "last": "Su"
                },
                {
                    "first": "Xiaoming",
                    "initial": "X.",
                    "last": "Li"
                },
                {
                    "first": "Ivan S.F.",
                    "initial": "I.S.F.",
                    "last": "Chan"
                },
                {
                    "first": "Janie",
                    "initial": "J.",
                    "last": "Parrino"
                },
                {
                    "first": "Paula",
                    "initial": "P.",
                    "last": "Annunziato"
                },
                {
                    "first": "Michael N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                },
                {
                    "first": "L. E.",
                    "initial": "L.E.",
                    "last": "Davis"
                },
                {
                    "first": "C. A.",
                    "initial": "C.A.",
                    "last": "Kauffman"
                },
                {
                    "first": "S. K.",
                    "initial": "S.K.",
                    "last": "Keay"
                },
                {
                    "first": "S. E.",
                    "initial": "S.E.",
                    "last": "Straus"
                },
                {
                    "first": "A. R.",
                    "initial": "A.R.",
                    "last": "Marques"
                },
                {
                    "first": "N. E.",
                    "initial": "N.E.",
                    "last": "Soto"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Brunell"
                },
                {
                    "first": "J. W.",
                    "initial": "J.W.",
                    "last": "Gnann"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Serrao"
                },
                {
                    "first": "D. J.",
                    "initial": "D.J.",
                    "last": "Cotton"
                },
                {
                    "first": "R. P.",
                    "initial": "R.P.",
                    "last": "Goodman"
                },
                {
                    "first": "R. D.",
                    "initial": "R.D.",
                    "last": "Arbeit"
                },
                {
                    "first": "C. T.",
                    "initial": "C.T.",
                    "last": "Pachucki"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "K. E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "W. A.",
                    "initial": "W.A.",
                    "last": "Keitel"
                },
                {
                    "first": "R. N.",
                    "initial": "R.N.",
                    "last": "Greenberg"
                },
                {
                    "first": "V. A.",
                    "initial": "V.A.",
                    "last": "Morrison"
                },
                {
                    "first": "P. F.",
                    "initial": "P.F.",
                    "last": "Wright"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Griffin"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Simberkoff"
                },
                {
                    "first": "S. S.",
                    "initial": "S.S.",
                    "last": "Yeh"
                },
                {
                    "first": "Z.",
                    "initial": "Z.",
                    "last": "Lobo"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Holodniy"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Loutit"
                },
                {
                    "first": "R. F.",
                    "initial": "R.F.",
                    "last": "Betts"
                },
                {
                    "first": "L. D.",
                    "initial": "L.D.",
                    "last": "Gelb"
                },
                {
                    "first": "G. E.",
                    "initial": "G.E.",
                    "last": "Crawford"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Guatelli"
                },
                {
                    "first": "P. A.",
                    "initial": "P.A.",
                    "last": "Brooks"
                },
                {
                    "first": "D. J.",
                    "initial": "D.J.",
                    "last": "Looney"
                },
                {
                    "first": "K. M.",
                    "initial": "K.M.",
                    "last": "Neuzil"
                },
                {
                    "first": "J. F.",
                    "initial": "J.F.",
                    "last": "Toney"
                },
                {
                    "first": "C. A.",
                    "initial": "C.A.",
                    "last": "Kauffman"
                },
                {
                    "first": "S. K.",
                    "initial": "S.K.",
                    "last": "Keay"
                },
                {
                    "first": "A. R.",
                    "initial": "A.R.",
                    "last": "Marques"
                },
                {
                    "first": "C. T.",
                    "initial": "C.T.",
                    "last": "Pachucki"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "K. E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "V. A.",
                    "initial": "V.A.",
                    "last": "Morrison"
                },
                {
                    "first": "P. F.",
                    "initial": "P.F.",
                    "last": "Wright"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Griffin"
                },
                {
                    "first": "R. F.",
                    "initial": "R.F.",
                    "last": "Betts"
                },
                {
                    "first": "L. D.",
                    "initial": "L.D.",
                    "last": "Gelb"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Guatelli"
                },
                {
                    "first": "D. J.",
                    "initial": "D.J.",
                    "last": "Looney"
                },
                {
                    "first": "K. M.",
                    "initial": "K.M.",
                    "last": "Neuzil"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Menzies"
                },
                {
                    "first": "J. F.",
                    "initial": "J.F.",
                    "last": "Toney"
                }
            ],
            "doi": "10.1093/cid/ciu918",
            "firstpage": "900",
            "issn": "10584838",
            "lastpage": "909",
            "pmid": "25416754",
            "pub_year": 2015,
            "title": "Long-term persistence of zoster vaccine efficacy",
            "volume": "60"
        },
        "b0125": null,
        "b0130": null,
        "b0135": null,
        "b0140": {
            "authors": [
                {
                    "first": "Bas",
                    "initial": "B.",
                    "last": "Janssen"
                },
                {
                    "first": "Agota",
                    "initial": "A.",
                    "last": "Szende"
                }
            ],
            "doi": "10.1007/978-94-007-7596-1_3",
            "firstpage": "19",
            "lastpage": "30",
            "pub_year": 2014,
            "title": "Population norms for the EQ-5D"
        },
        "b0145": {
            "authors": [
                {
                    "first": "James M.",
                    "initial": "J.M.",
                    "last": "Pellissier"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Brisson"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                }
            ],
            "doi": "10.1016/j.vaccine.2007.09.066",
            "firstpage": "8326",
            "issn": "0264410X",
            "lastpage": "8337",
            "pmid": "17980938",
            "pub_year": 2007,
            "title": "Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults",
            "volume": "25"
        },
        "b0150": null,
        "b0155": {
            "authors": [
                {
                    "first": "Michael B.",
                    "initial": "M.B.",
                    "last": "Rothberg"
                },
                {
                    "first": "Anunta",
                    "initial": "A.",
                    "last": "Virapongse"
                },
                {
                    "first": "Kenneth J.",
                    "initial": "K.J.",
                    "last": "Smith"
                }
            ],
            "doi": "10.1086/514342",
            "firstpage": "1280",
            "issn": "10584838",
            "lastpage": "1288",
            "pmid": "17443464",
            "pub_year": 2007,
            "title": "Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults",
            "volume": "44"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Phuc",
                    "initial": "P.",
                    "last": "Le"
                },
                {
                    "first": "Michael B.",
                    "initial": "M.B.",
                    "last": "Rothberg"
                }
            ],
            "doi": "10.7326/M15-0093",
            "firstpage": "489",
            "issn": "00034819",
            "lastpage": "497",
            "pmid": "26344036",
            "pub_year": 2015,
            "title": "Cost-effectiveness of herpes zoster vaccine for persons aged 50 years",
            "volume": "163"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Phuc",
                    "initial": "P.",
                    "last": "Le"
                },
                {
                    "first": "Michael B.",
                    "initial": "M.B.",
                    "last": "Rothberg"
                }
            ],
            "doi": "10.1007/s11606-016-3844-6",
            "firstpage": "159",
            "issn": "08848734",
            "lastpage": "167",
            "pmid": "27743284",
            "pub_year": 2017,
            "title": "Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis",
            "volume": "32"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Phuc",
                    "initial": "P.",
                    "last": "Le"
                },
                {
                    "first": "Michael B.",
                    "initial": "M.B.",
                    "last": "Rothberg"
                }
            ],
            "doi": "10.1001/jamainternmed.2017.7431",
            "firstpage": "248",
            "issn": "21686106",
            "lastpage": "258",
            "pmid": "29297049",
            "pub_year": 2018,
            "title": "Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults",
            "volume": "178"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Mehdi",
                    "initial": "M.",
                    "last": "Najafzadeh"
                }
            ],
            "doi": "10.1001/jamainternmed.2017.7442",
            "firstpage": "258",
            "issn": "21686106",
            "lastpage": "259",
            "pmid": "29297047",
            "pub_year": 2018,
            "title": "Evolution of herpes zoster vaccines and their economic value",
            "volume": "178"
        },
        "b0180": null,
        "b0185": {
            "authors": [
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Stephanie",
                    "initial": "S.",
                    "last": "Volpe"
                },
                {
                    "first": "Gregory",
                    "initial": "G.",
                    "last": "Catteau"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Marie Pierre",
                    "initial": "M.P.",
                    "last": "David"
                },
                {
                    "first": "Jan Hendrik",
                    "initial": "J.H.",
                    "last": "Richardus"
                },
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "Lidia",
                    "initial": "L.",
                    "last": "Oostvogels"
                },
                {
                    "first": "Karlis",
                    "initial": "K.",
                    "last": "Pauksens"
                },
                {
                    "first": "Stephanie",
                    "initial": "S.",
                    "last": "Ravault"
                },
                {
                    "first": "Lars",
                    "initial": "L.",
                    "last": "Rombo"
                },
                {
                    "first": "Gerard",
                    "initial": "G.",
                    "last": "Sonder"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Smetana"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Heineman"
                },
                {
                    "first": "Adriana",
                    "initial": "A.",
                    "last": "Bastidas"
                }
            ],
            "doi": "10.1080/21645515.2018.1442162",
            "firstpage": "1370",
            "issn": "21645515",
            "lastpage": "1377",
            "pmid": "29461919",
            "pub_year": 2018,
            "title": "Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults",
            "volume": "14"
        },
        "b0190": {
            "authors": [
                {
                    "first": "Desmond",
                    "initial": "D.",
                    "last": "Curran"
                },
                {
                    "first": "Lidia",
                    "initial": "L.",
                    "last": "Oostvogels"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Heineman"
                },
                {
                    "first": "Sean",
                    "initial": "S.",
                    "last": "Matthews"
                },
                {
                    "first": "Janet",
                    "initial": "J.",
                    "last": "McElhaney"
                },
                {
                    "first": "Shelly",
                    "initial": "S.",
                    "last": "McNeil"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Diez-Domingo"
                },
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "Charles",
                    "initial": "C.",
                    "last": "Andrews"
                },
                {
                    "first": "Eugene",
                    "initial": "E.",
                    "last": "Athan"
                },
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Berglund"
                },
                {
                    "first": "Laura",
                    "initial": "L.",
                    "last": "Campora"
                },
                {
                    "first": "Ferdinandus",
                    "initial": "F.",
                    "last": "De Looze"
                },
                {
                    "first": "Tiina",
                    "initial": "T.",
                    "last": "Korhonen"
                },
                {
                    "first": "Edward",
                    "initial": "E.",
                    "last": "Leung"
                },
                {
                    "first": "Myron",
                    "initial": "M.",
                    "last": "Levin"
                },
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Volpi"
                },
                {
                    "first": "Robert W.",
                    "initial": "R.W.",
                    "last": "Johnson"
                }
            ],
            "doi": "10.1093/gerona/gly150",
            "firstpage": "1231",
            "issn": "10795006",
            "lastpage": "1238",
            "pmid": "29955836",
            "pub_year": 2019,
            "title": "Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older",
            "volume": "74"
        },
        "b0195": {
            "authors": [
                {
                    "first": "Jennifer C.",
                    "initial": "J.C.",
                    "last": "Nelson"
                },
                {
                    "first": "Rachel C.L.",
                    "initial": "R.C.L.",
                    "last": "Bittner"
                },
                {
                    "first": "Lora",
                    "initial": "L.",
                    "last": "Bounds"
                },
                {
                    "first": "Shanshan",
                    "initial": "S.",
                    "last": "Zhao"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Baggs"
                },
                {
                    "first": "James G.",
                    "initial": "J.G.",
                    "last": "Donahue"
                },
                {
                    "first": "Simon J.",
                    "initial": "S.J.",
                    "last": "Hambidge"
                },
                {
                    "first": "Steven J.",
                    "initial": "S.J.",
                    "last": "Jacobsen"
                },
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Allison L.",
                    "initial": "A.L.",
                    "last": "Naleway"
                },
                {
                    "first": "Kenneth M.",
                    "initial": "K.M.",
                    "last": "Zangwill"
                },
                {
                    "first": "Lisa A.",
                    "initial": "L.A.",
                    "last": "Jackson"
                }
            ],
            "doi": "10.2105/AJPH.2008.151332",
            "firstpage": "S389",
            "issn": "00900036",
            "lastpage": "S397",
            "pmid": "19797753",
            "pub_year": 2009,
            "title": "Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: Results from a vaccine safety datalink study",
            "volume": "99"
        },
        "b0200": null,
        "b0205": {
            "authors": [
                {
                    "first": "Barbara P.",
                    "initial": "B.P.",
                    "last": "Yawn"
                },
                {
                    "first": "Robbin F.",
                    "initial": "R.F.",
                    "last": "Itzler"
                },
                {
                    "first": "Peter C.",
                    "initial": "P.C.",
                    "last": "Wollan"
                },
                {
                    "first": "James M.",
                    "initial": "J.M.",
                    "last": "Pellissier"
                },
                {
                    "first": "Lina S.",
                    "initial": "L.S.",
                    "last": "Sy"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Saddier"
                }
            ],
            "doi": "10.4065/84.9.787",
            "firstpage": "787",
            "issn": "00256196",
            "lastpage": "794",
            "pub_year": 2009,
            "title": "Health care utilization and cost burden of herpes zoster in a community population",
            "volume": "84"
        }
    },
    "body_text": [
        {
            "endOffset": 23032,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 23031,
                    "startOffset": 23024
                },
                "b0080": {
                    "endOffset": 22859,
                    "startOffset": 22855
                },
                "b0085": {
                    "endOffset": 23031,
                    "startOffset": 23024
                }
            },
            "secId": "s0005",
            "sentence": "Whereas ZVL demonstrated efficacy results against HZ of 69.8% in individuals aged 50\u201359 YOA [16], decreasing to 37.6% in individuals aged 70+ YOA, RZV demonstrated efficacy results against HZ of 97.2% in subjects aged 50+ YOA and 91.3% in subjects aged 70+ YOA [15,17].",
            "startOffset": 22763,
            "title": "Introduction"
        },
        {
            "endOffset": 30592,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0135": {
                    "endOffset": 30529,
                    "startOffset": 30525
                }
            },
            "secId": "s0025",
            "sentence": "The administration cost per dose was taken from Ortega-Sanchez [27], who reported $20 administration cost for ZVL (range $15\u2013$50).",
            "startOffset": 30462,
            "title": "Model inputs"
        },
        {
            "endOffset": 33120,
            "parents": [],
            "secId": "s0035",
            "sentence": "This reduced disease burden would result in a gain of 77 discounted life-years and 2291 discounted QALYs.",
            "startOffset": 33015,
            "title": "Results"
        },
        {
            "endOffset": 31195,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The results of the DSA were summarized in a tornado diagram.",
            "startOffset": 31135,
            "title": "Sensitivity and scenario analyses"
        },
        {
            "endOffset": 29226,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Based on the data from the clinical trials, it was assumed that for individuals aged 50\u201369 YOA receiving 2-doses of RZV, the HZ VE was assumed to wane at 1% annually during the first four years post-vaccination, 2.3% during the subsequent years until the age of 69, and 3.6% for all individuals aged 70+ YOA.",
            "startOffset": 28918,
            "title": "Model inputs"
        },
        {
            "endOffset": 27854,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Based on the data from the clinical trials, it was assumed that for individuals aged 50\u201369 YOA receiving 2-doses of RZV, the HZ VE was assumed to wane at 1% annually during the first four years post-vaccination, 2.3% during the subsequent years until the age of 69, and 3.6% for all individuals aged 70+ YOA.",
            "startOffset": 27546,
            "title": "Model inputs"
        },
        {
            "endOffset": 31407,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "A probabilistic sensitivity analyses (PSA) was conducted to consider the impact of the full uncertainty in model inputs and to explore the impact on the ICER of (a) RZV versus No Vaccine, and (b) RZV versus ZVL.",
            "startOffset": 31196,
            "title": "Sensitivity and scenario analyses"
        },
        {
            "endOffset": 34901,
            "parents": [],
            "secId": "s0035",
            "sentence": "The majority (72%) of individual (versus grouped) inputs did not shift the ICER by more than $5000 in either direction.",
            "startOffset": 34782,
            "title": "Results"
        },
        {
            "endOffset": 38346,
            "parents": [],
            "secId": "s0040",
            "sentence": "It was demonstrated that the RZV vaccine would be cost-effective compared to a No Vaccine strategy and cost-saving compared to ZVL vaccination.",
            "startOffset": 38203,
            "title": "Discussion"
        },
        {
            "endOffset": 35257,
            "parents": [],
            "secId": "s0035",
            "sentence": "Results of the PSA for the RZV versus ZVL are presented in Fig. 2.",
            "startOffset": 35191,
            "title": "Results"
        },
        {
            "endOffset": 41902,
            "parents": [],
            "secId": "s0040",
            "sentence": "Wide ranges of values were considered for both efficacy and waning of efficacy against HZ for RZV 1-dose.",
            "startOffset": 41797,
            "title": "Discussion"
        },
        {
            "endOffset": 20703,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 20702,
                    "startOffset": 20699
                }
            },
            "secId": "s0005",
            "sentence": "Herpes zoster (HZ, shingles) is a viral infection elicited by the reactivation of varicella-zoster virus (VZV, chickenpox) [1].",
            "startOffset": 20576,
            "title": "Introduction"
        },
        {
            "endOffset": 26848,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 26847,
                    "startOffset": 26840
                },
                "b0115": {
                    "endOffset": 26847,
                    "startOffset": 26840
                }
            },
            "secId": "s0025",
            "sentence": "The VE for ZVL was from the Shingles Prevention Study (SPS) and Zoster Efficacy and Safety Study (ZEST) [16,23].",
            "startOffset": 26736,
            "title": "Model inputs"
        },
        {
            "endOffset": 29437,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Coverage of the first dose for both vaccines was assumed to be 100%.",
            "startOffset": 29369,
            "title": "Model inputs"
        },
        {
            "endOffset": 27489,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0075": {
                    "endOffset": 27488,
                    "startOffset": 27481
                },
                "b0085": {
                    "endOffset": 27488,
                    "startOffset": 27481
                }
            },
            "secId": "s0025",
            "sentence": "The VE of RZV against HZ and PHN was taken from the ZOE-50 and ZOE-70 studies [15,17].",
            "startOffset": 27403,
            "title": "Model inputs"
        },
        {
            "endOffset": 34632,
            "parents": [],
            "secId": "s0035",
            "sentence": "The tornado diagram shows that the ICER was most sensitive to the following inputs based on their defined ranges: (i) annual waning of VE for RZV (one-dose and two-dose for all ages pooled), (ii) annual incidence of initial HZ, (iii) discount rate for costs and health outcomes pooled, (iv) annual waning of RZV (two-dose) efficacy for 70+ YOA, and (v) discount rate for costs.",
            "startOffset": 34255,
            "title": "Results"
        },
        {
            "endOffset": 38542,
            "parents": [],
            "refoffsets": {
                "b0150": {
                    "endOffset": 38541,
                    "startOffset": 38531
                },
                "b0170": {
                    "endOffset": 38541,
                    "startOffset": 38531
                },
                "b0200": {
                    "endOffset": 38541,
                    "startOffset": 38531
                }
            },
            "secId": "s0040",
            "sentence": "One of the strengths of our model is that it is quite consistent with respect to inputs and outcomes compared with an independently developed model and the CDC model presented at ACIP [30,34,40].",
            "startOffset": 38347,
            "title": "Discussion"
        },
        {
            "endOffset": 26397,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Further details are provided in the Supplementary Text.",
            "startOffset": 26342,
            "title": "Model inputs"
        },
        {
            "endOffset": 24564,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0100": {
                    "endOffset": 24563,
                    "startOffset": 24559
                }
            },
            "secId": "s0015",
            "sentence": "Further details regarding the model structure are provided in the supplementary text and elsewhere [20].",
            "startOffset": 24460,
            "title": "Mathematical model"
        },
        {
            "endOffset": 27402,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "In the model, both the HZ and PHN year 1 VE estimates are based on adjusted overall study VE, i.e. the overall VE estimates, which were estimated over \u22653 years, are adjusted upwards to take into account the waning during the clinical trial follow-up period.",
            "startOffset": 27145,
            "title": "Model inputs"
        },
        {
            "endOffset": 43672,
            "parents": [],
            "secId": "s0040",
            "sentence": "Another limitation of the study is the uncertainty regarding real-life, multi-dose compliance in older adults.",
            "startOffset": 43562,
            "title": "Discussion"
        },
        {
            "endOffset": 21379,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 21378,
                    "startOffset": 21373
                },
                "b0040": {
                    "endOffset": 21378,
                    "startOffset": 21373
                }
            },
            "secId": "s0005",
            "sentence": "HZ and its associated complications have a significant negative impact upon patient quality of life with physical, psychological, social and functional health domains being greatly affected [7,8].",
            "startOffset": 21183,
            "title": "Introduction"
        },
        {
            "endOffset": 36347,
            "parents": [],
            "secId": "s0035",
            "sentence": "Similarly, the model estimated that incidence of initial HZ could be about 30% less than base-case estimates and still result in ICERs of less than a threshold of $70,000 per QALY.",
            "startOffset": 36167,
            "title": "Results"
        },
        {
            "endOffset": 20918,
            "parents": [],
            "secId": "s0005",
            "sentence": "HZ typically presents as an acute, painful, vesicular eruption distributed along a single dermatome.",
            "startOffset": 20818,
            "title": "Introduction"
        },
        {
            "endOffset": 24343,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The model follows all subjects within a cohort over their remaining lifetimes from the year of vaccination with annual cycle lengths.",
            "startOffset": 24210,
            "title": "Mathematical model"
        },
        {
            "endOffset": 24795,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "It is a multi-cohort Markov model including five hypothetical cohorts split into age groups for people aged 50+ YOA (i.e. 50\u201359, 60\u201364, 65\u201369, 70\u201379, 80+).",
            "startOffset": 24640,
            "title": "Mathematical model"
        },
        {
            "endOffset": 43379,
            "parents": [],
            "secId": "s0040",
            "sentence": "A limitation of this study is that efficacy data and HZ incidence data were based on immunocompetent individuals only.",
            "startOffset": 43261,
            "title": "Discussion"
        },
        {
            "endOffset": 22277,
            "parents": [],
            "secId": "s0005",
            "sentence": "It is a one-dose live-attenuated vaccine that utilizes the same Oka strain as in varicella vaccines but at a higher potency.",
            "startOffset": 22153,
            "title": "Introduction"
        },
        {
            "endOffset": 31521,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The results of the PSA were presented on a cost-effectiveness plane and a cost-effectiveness acceptability curve.",
            "startOffset": 31408,
            "title": "Sensitivity and scenario analyses"
        },
        {
            "endOffset": 32539,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Finally, we performed an analysis to answer the question: at which age did vaccination (i.e. 50, 60, 65, 70 and 80 YOA) yield the lowest ICER?",
            "startOffset": 32397,
            "title": "Sensitivity and scenario analyses"
        },
        {
            "endOffset": 39365,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 39364,
                    "startOffset": 39357
                },
                "b0155": {
                    "endOffset": 39364,
                    "startOffset": 39357
                }
            },
            "secId": "s0040",
            "sentence": "In 2007, two key studies were published reporting the cost-effectiveness of vaccinating US adults with ZVL using VE estimates from the SPS trial [29,31].",
            "startOffset": 39212,
            "title": "Discussion"
        },
        {
            "endOffset": 42735,
            "parents": [],
            "secId": "s0040",
            "sentence": "However, given that the same study has shown that the immune responses two months following either a single dose of either 50\u03bcgE/AS01B or a single dose of 100\u03bcgE/AS01B are comparable, it is plausible to assume that the long-term data can be generally extrapolated to the RZV.",
            "startOffset": 42460,
            "title": "Discussion"
        },
        {
            "endOffset": 33396,
            "parents": [],
            "secId": "s0035",
            "sentence": "The vaccination costs would total $304 million dollars, but the HZ cases prevented would save $208 million in direct costs and $68 million in indirect costs, resulting in a net total societal cost of vaccinating that cohort of 1 million adults of approximately $27.2 million.",
            "startOffset": 33121,
            "title": "Results"
        },
        {
            "endOffset": 44948,
            "parents": [],
            "secId": "s0050",
            "sentence": "DC, PB, BL, BP, DVO, LV and BY participated in the conception and design of the study.",
            "startOffset": 44862,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 31871,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "We conducted two sets of scenario analyses, both comparing RZV with No Vaccine.",
            "startOffset": 31792,
            "title": "Sensitivity and scenario analyses"
        },
        {
            "endOffset": 22701,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 22700,
                    "startOffset": 22696
                }
            },
            "secId": "s0005",
            "sentence": "RZV combines gE, a protein found on the VZV that causes shingles, with an adjuvant system, AS01B, which is intended to enhance the immunological response to the antigen [15].",
            "startOffset": 22527,
            "title": "Introduction"
        },
        {
            "endOffset": 42103,
            "parents": [],
            "secId": "s0040",
            "sentence": "Compliance for the second dose of RZV was very high, i.e. approximately 95%, in both the ZOE-50 and ZOE-70 clinical trials, so there were limited efficacy data on individuals who received only 1 dose.",
            "startOffset": 41903,
            "title": "Discussion"
        },
        {
            "endOffset": 35855,
            "parents": [],
            "secId": "s0035",
            "sentence": "The results of the threshold analyses for RZV versus No Vaccine are presented in Fig. 3.",
            "startOffset": 35767,
            "title": "Results"
        },
        {
            "endOffset": 40394,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 40393,
                    "startOffset": 40389
                }
            },
            "secId": "s0040",
            "sentence": "A model by Le and Rothberg assumed that vaccine efficacy of RZV 2-dose and ZVL would wane at the same rates (5.4% per year) [34].",
            "startOffset": 40265,
            "title": "Discussion"
        },
        {
            "endOffset": 35623,
            "parents": [],
            "secId": "s0035",
            "sentence": "Approximately 98% of simulations and 99.5% of simulations resulted in costs per QALY gained by RZV versus No Vaccine below thresholds of $80,000 and $100,000, respectively.",
            "startOffset": 35451,
            "title": "Results"
        },
        {
            "endOffset": 28220,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 28219,
                    "startOffset": 28212
                },
                "b0115": {
                    "endOffset": 28219,
                    "startOffset": 28212
                }
            },
            "secId": "s0025",
            "sentence": "The VE for ZVL was from the Shingles Prevention Study (SPS) and Zoster Efficacy and Safety Study (ZEST) [16,23].",
            "startOffset": 28108,
            "title": "Model inputs"
        },
        {
            "endOffset": 27997,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "In the absence of long-term VE data, we assumed that the VE for 1-dose of RZV against both HZ and PHN waned at the same rate as the VE of ZVL.",
            "startOffset": 27855,
            "title": "Model inputs"
        },
        {
            "endOffset": 30326,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The RZV price per dose was assumed to be $140 with a range of $125\u2013$175 used in deterministic sensitivity and scenario analysis.",
            "startOffset": 30198,
            "title": "Model inputs"
        },
        {
            "endOffset": 32097,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "In the first set, we varied the values of second-dose compliance for RZV, VE and waning of VE for RZV for 1 and 2 doses values, and weighted cost of AEs per vaccine dose; the scenarios are listed in Supplemental Text Table 5.",
            "startOffset": 31872,
            "title": "Sensitivity and scenario analyses"
        },
        {
            "endOffset": 32945,
            "parents": [],
            "secId": "s0035",
            "sentence": "The model estimated that, compared to not vaccinating against HZ, RZV would prevent 103,603 HZ cases, 11,197 PHN cases and 14,455 other complications, over the remaining lifetimes of all individuals included in the model.",
            "startOffset": 32724,
            "title": "Results"
        },
        {
            "endOffset": 41091,
            "parents": [],
            "secId": "s0040",
            "sentence": "Some differences did exist, in particular with respect to age groups participating, and while the SPS study included US sites only, the ZOE studies were conducted in 18 countries worldwide.",
            "startOffset": 40902,
            "title": "Discussion"
        },
        {
            "endOffset": 22526,
            "parents": [],
            "secId": "s0005",
            "sentence": "The Adjuvanted Recombinant Zoster Vaccine (RZV, Shingrix) is a non-live subunit vaccine developed to be administered in a 2-dose schedule, as 2 doses produced a 3-fold higher glycoprotein E (gE)-specific cell mediated immune response than one dose.",
            "startOffset": 22278,
            "title": "Introduction"
        },
        {
            "endOffset": 35690,
            "parents": [],
            "secId": "s0035",
            "sentence": "Results of the PSA for the RZV versus ZVL are presented in Fig. 2.",
            "startOffset": 35624,
            "title": "Results"
        },
        {
            "endOffset": 41277,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 41276,
                    "startOffset": 41272
                }
            },
            "secId": "s0040",
            "sentence": "For RZV 2-doses, waning was estimated to be 1% (95% confidence intervals 0\u20132.6%) and 3.6% (95% confidence intervals 1.4\u20136.6%) in the ZOE-50 and ZOE-70 pooled analysis respectively [20].",
            "startOffset": 41092,
            "title": "Discussion"
        },
        {
            "endOffset": 28382,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 28381,
                    "startOffset": 28377
                }
            },
            "secId": "s0025",
            "sentence": "The persistence of VE against HZ for ZVL was modelled based on the data from the SPS and the subsequent persistence studies as presented by Morrison et al. [24].",
            "startOffset": 28221,
            "title": "Model inputs"
        },
        {
            "endOffset": 34254,
            "parents": [],
            "secId": "s0035",
            "sentence": "The results of the DSA for the analysis of RZV versus No Vaccine for US adults aged 60+ YOA are presented in Fig. 1.",
            "startOffset": 34138,
            "title": "Results"
        },
        {
            "endOffset": 43794,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 43793,
                    "startOffset": 43786
                },
                "b0195": {
                    "endOffset": 43793,
                    "startOffset": 43786
                }
            },
            "secId": "s0040",
            "sentence": "Nevertheless, a wide range of values were selected to reflect uncertainty regarding this parameter (i.e. 45\u201389%) [19,39].",
            "startOffset": 43673,
            "title": "Discussion"
        },
        {
            "endOffset": 25266,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Three different HZ vaccination strategies are compared: No Vaccine, vaccination with ZVL, and vaccination with RZV.",
            "startOffset": 25151,
            "title": "Mathematical model"
        },
        {
            "endOffset": 26520,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 26462,
                    "startOffset": 26458
                },
                "b0110": {
                    "endOffset": 26519,
                    "startOffset": 26515
                }
            },
            "secId": "s0025",
            "sentence": "US population sizes by age group were from the Census Bureau [21] and all-cause mortality rates (%) from Arias et al. [22].",
            "startOffset": 26397,
            "title": "Model inputs"
        },
        {
            "endOffset": 23988,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "It is a multi-cohort Markov model including five hypothetical cohorts split into age groups for people aged 50+ YOA (i.e. 50\u201359, 60\u201364, 65\u201369, 70\u201379, 80+).",
            "startOffset": 23833,
            "title": "Mathematical model"
        },
        {
            "endOffset": 43008,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 42817,
                    "startOffset": 42813
                }
            },
            "secId": "s0040",
            "sentence": "Pellisier et al. [29] reported that subjects vaccinated with ZVL who went on to develop HZ and PHN had reduced utility losses from HZ and PHN compared to unvaccinated subjects who also developed those conditions.",
            "startOffset": 42796,
            "title": "Discussion"
        },
        {
            "endOffset": 21077,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 21076,
                    "startOffset": 21073
                }
            },
            "secId": "s0005",
            "sentence": "The acute pain may last for weeks evolving into postherpetic neuralgia (PHN), frequently defined as pain persisting or appearing 90 days after rash onset [3].",
            "startOffset": 20919,
            "title": "Introduction"
        },
        {
            "endOffset": 37305,
            "parents": [],
            "secId": "s0035",
            "sentence": "They show that the cost-effectiveness of using RZV to vaccinate US adults aged 60+ YOA was robust to multiple combinations of unfavorable values for RZV for several of the key inputs.",
            "startOffset": 37122,
            "title": "Results"
        },
        {
            "endOffset": 22762,
            "parents": [],
            "secId": "s0005",
            "sentence": "Large clinical trials have been conducted for both vaccines.",
            "startOffset": 22702,
            "title": "Introduction"
        },
        {
            "endOffset": 37689,
            "parents": [],
            "secId": "s0035",
            "sentence": "In the analysis from the health sector perspective, comparing RZV versus no vaccine for vaccinating US adults aged 60+ YOA, the model estimated an ICER of $38,867 per QALY gained.",
            "startOffset": 37510,
            "title": "Results"
        },
        {
            "endOffset": 27545,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Further details are provided in the supplementary text.",
            "startOffset": 27490,
            "title": "Model inputs"
        },
        {
            "endOffset": 43561,
            "parents": [],
            "secId": "s0040",
            "sentence": "As efficacy data become available for RZV in immunocompromised individuals, additional cost-effectiveness analyses that consider immunocompromised populations should be carried out.",
            "startOffset": 43380,
            "title": "Discussion"
        },
        {
            "endOffset": 27010,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 27009,
                    "startOffset": 27005
                }
            },
            "secId": "s0025",
            "sentence": "The persistence of VE against HZ for ZVL was modelled based on the data from the SPS and the subsequent persistence studies as presented by Morrison et al. [24].",
            "startOffset": 26849,
            "title": "Model inputs"
        },
        {
            "endOffset": 30461,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0130": {
                    "endOffset": 30460,
                    "startOffset": 30456
                }
            },
            "secId": "s0025",
            "sentence": "The ZVL price per dose was assumed to be $196.91 based on the private sector price per dose listed in the CDC Vaccine Price List [26].",
            "startOffset": 30327,
            "title": "Model inputs"
        },
        {
            "endOffset": 45039,
            "parents": [],
            "secId": "s0050",
            "sentence": "DC, JC, KH, BP, DVO and LV participated in the collection or generation of the study data.",
            "startOffset": 44949,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 42459,
            "parents": [],
            "secId": "s0040",
            "sentence": "The long-term immunogenicity data following a single dose administration regimen have been generated with a formulation which contained double the dose of gE, compared to RZV.",
            "startOffset": 42284,
            "title": "Discussion"
        },
        {
            "endOffset": 23406,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 23405,
                    "startOffset": 23401
                }
            },
            "secId": "s0005",
            "sentence": "The ACIP recommendations were made based on clinical efficacy data, health economic evidence, and immunogenicity data [19].",
            "startOffset": 23283,
            "title": "Introduction"
        },
        {
            "endOffset": 41567,
            "parents": [],
            "refoffsets": {
                "b0180": {
                    "endOffset": 41566,
                    "startOffset": 41562
                }
            },
            "secId": "s0040",
            "sentence": "In the meantime, results of a phase IIIB, open-label study following participants who had received two doses of RZV for up to 9 years after the first dose to determine the persistence of the immune response have become available [36].",
            "startOffset": 41333,
            "title": "Discussion"
        },
        {
            "endOffset": 44500,
            "parents": [],
            "secId": "s0040",
            "sentence": "In this paper we have also shown that vaccination against HZ with RZV is cost-effective compared to No Vaccine and cost-saving compared to ZVL in the US population aged 60 YOA and over.",
            "startOffset": 44315,
            "title": "Discussion"
        },
        {
            "endOffset": 26038,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Data for populating the model were taken from the published literature and national survey data sources.",
            "startOffset": 25934,
            "title": "Model inputs"
        },
        {
            "endOffset": 26341,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Data for populating the model were taken from the published literature and national survey data sources.",
            "startOffset": 26237,
            "title": "Model inputs"
        },
        {
            "endOffset": 21897,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 21788,
                    "startOffset": 21784
                },
                "b0055": {
                    "endOffset": 21896,
                    "startOffset": 21892
                }
            },
            "secId": "s0005",
            "sentence": "HZ and related complications are estimated to result in approximately $1.3 billion in medical care costs and $1.7 billion in indirect costs annually [10]; and this burden is projected to rise substantially over the coming years due to the aging populations [11].",
            "startOffset": 21635,
            "title": "Introduction"
        },
        {
            "endOffset": 25658,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "In the base-case analysis we evaluated the incremental cost-effectiveness ratio (ICER), in terms of cost per additional quality-adjusted life-year (QALY) gained, of vaccinating a cohort of 1 million individuals aged 60+ YOA in the age-specific US population.",
            "startOffset": 25400,
            "title": "Methodological assumptions"
        },
        {
            "endOffset": 28516,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Waning of VE for ZVL against HZ was estimated to be 5.4% per year during the first 4 years following vaccination and 5.1% thereafter.",
            "startOffset": 28383,
            "title": "Model inputs"
        },
        {
            "endOffset": 31041,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "A weighted AE-related QALY loss per dose was calculated based on the proportion of subjects with a local/general reaction and the proportion with a serious event.",
            "startOffset": 30879,
            "title": "Model inputs"
        },
        {
            "endOffset": 34138,
            "parents": [],
            "secId": "s0035",
            "sentence": "The number needed to vaccinate to prevent one HZ cases was estimated to be 10 for RZV and 32 for ZVL.",
            "startOffset": 34037,
            "title": "Results"
        },
        {
            "endOffset": 23832,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The ZOster ecoNomic Analysis (ZONA) model was developed in Microsoft Excel.",
            "startOffset": 23757,
            "title": "Mathematical model"
        },
        {
            "endOffset": 36166,
            "parents": [],
            "secId": "s0035",
            "sentence": "The model estimated that the initial efficacy of RZV for 2 doses could be roughly 30% lower than the base-case (much lower than the lower bound of the 95% confidence interval observed in the clinical trial results) and still result in an ICER of RZV versus No Vaccine less than a threshold of $80,000 per QALY.",
            "startOffset": 35856,
            "title": "Results"
        },
        {
            "endOffset": 33618,
            "parents": [],
            "secId": "s0035",
            "sentence": "Compared to ZVL, the model estimated that RZV would prevent 71,638 additional HZ cases, 6403 PHN cases, 10,582 other complications, and 13 HZ-related deaths.",
            "startOffset": 33461,
            "title": "Results"
        },
        {
            "endOffset": 44190,
            "parents": [],
            "refoffsets": {
                "b0200": {
                    "endOffset": 44189,
                    "startOffset": 44182
                },
                "b0205": {
                    "endOffset": 44189,
                    "startOffset": 44182
                }
            },
            "secId": "s0040",
            "sentence": "As with the CDC model, presented at ACIP 2017, one additional limitation of our model was that many of the epidemiological and cost input parameters were based on a population based study in a single county in Minnesota [40,41].",
            "startOffset": 43962,
            "title": "Discussion"
        },
        {
            "endOffset": 22039,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 22038,
                    "startOffset": 22031
                },
                "b0065": {
                    "endOffset": 22038,
                    "startOffset": 22031
                }
            },
            "secId": "s0005",
            "sentence": "Since 2008, the Advisory Committee on Immunization Practices (ACIP) has recommended that adults aged 60+ YOA be vaccinated against HZ [12,13].",
            "startOffset": 21897,
            "title": "Introduction"
        },
        {
            "endOffset": 38981,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 38980,
                    "startOffset": 38977
                }
            },
            "secId": "s0040",
            "sentence": "A recent literature review of ZVL cost-effectiveness studies reported diverging results [3].",
            "startOffset": 38889,
            "title": "Discussion"
        },
        {
            "endOffset": 32723,
            "parents": [],
            "secId": "s0035",
            "sentence": "The results of the base cost-effectiveness analysis of RZV versus No Vaccine and versus ZVL for a cohort of 1 million US adults aged 60+ YOA in the US are presented in Table 3.",
            "startOffset": 32547,
            "title": "Results"
        },
        {
            "endOffset": 35334,
            "parents": [],
            "secId": "s0035",
            "sentence": "99% of simulations resulted in cost savings from RZV when compared with ZVL.",
            "startOffset": 35258,
            "title": "Results"
        },
        {
            "endOffset": 29492,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "We assumed that RZV doses were given two months apart.",
            "startOffset": 29438,
            "title": "Model inputs"
        },
        {
            "endOffset": 35767,
            "parents": [],
            "secId": "s0035",
            "sentence": "99% of simulations resulted in cost savings from RZV when compared with ZVL.",
            "startOffset": 35691,
            "title": "Results"
        },
        {
            "endOffset": 30197,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Table 2 presents the cost and utility inputs in the base-case, sensitivity, and scenario analyses.",
            "startOffset": 30099,
            "title": "Model inputs"
        },
        {
            "endOffset": 45251,
            "parents": [],
            "secId": "s0050",
            "sentence": "DC, PB, JC, KH, BL, BP, DVO, LV and BY were involved in the analysis or interpretation of the data.",
            "startOffset": 45152,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 29691,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0125": {
                    "endOffset": 29690,
                    "startOffset": 29686
                }
            },
            "secId": "s0025",
            "sentence": "Compliance of the second dose of RZV was assumed to be 69% (range: 45\u201389%) in the base-case based on the vaccination series completion and compliance rates of hepatitis A and B among US adults [25].",
            "startOffset": 29493,
            "title": "Model inputs"
        },
        {
            "endOffset": 45151,
            "parents": [],
            "secId": "s0050",
            "sentence": "DC, PB, JC, KH, BL, BP and DVO contributed to the material.",
            "startOffset": 45092,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 45091,
            "parents": [],
            "secId": "s0050",
            "sentence": "DC, PB, JC, KH, BP, DVO and LV performed the study.",
            "startOffset": 45040,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 37121,
            "parents": [],
            "secId": "s0035",
            "sentence": "The results of the first set of scenario analyses for RZV versus No Vaccine for US adults aged 60+ YOA are presented in Supplemental Text Table 5.",
            "startOffset": 36975,
            "title": "Results"
        },
        {
            "endOffset": 25016,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "When considering vaccination scenarios, for example directed at ages 60+, the model assumes that all of the subjects in the 60\u201364, 65\u201369, 70\u201379 and 80+ age cohorts are vaccinated, as would occur in a \u2018catch-up\u2019 campaign.",
            "startOffset": 24796,
            "title": "Mathematical model"
        },
        {
            "endOffset": 24209,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "When considering vaccination scenarios, for example directed at ages 60+, the model assumes that all of the subjects in the 60\u201364, 65\u201369, 70\u201379 and 80+ age cohorts are vaccinated, as would occur in a \u2018catch-up\u2019 campaign.",
            "startOffset": 23989,
            "title": "Mathematical model"
        },
        {
            "endOffset": 44713,
            "parents": [],
            "secId": "s0040",
            "sentence": "This evidence provides additional information for clinicians, payers and policy makers, and may help in their assessment of the value of vaccination against HZ, in order to reduce the burden of disease in the US.",
            "startOffset": 44501,
            "title": "Discussion"
        },
        {
            "endOffset": 25919,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Life years, QALYs, and costs were discounted at 3% per year.",
            "startOffset": 25859,
            "title": "Methodological assumptions"
        },
        {
            "endOffset": 26237,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.vaccine.2018.07.005.",
            "startOffset": 26103,
            "title": "Model inputs"
        },
        {
            "endOffset": 38889,
            "parents": [],
            "secId": "s0040",
            "sentence": "In our study, although there is considerable uncertainty in many of the parameters, the results were robust to a variety of sensitivity and scenario analyses.",
            "startOffset": 38731,
            "title": "Discussion"
        },
        {
            "endOffset": 39781,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 39708,
                    "startOffset": 39704
                }
            },
            "secId": "s0040",
            "sentence": "For example, in the model by Hales et al. [13] VE against herpes zoster for ZVL was assumed to wane to 0 over 10 years.",
            "startOffset": 39662,
            "title": "Discussion"
        },
        {
            "endOffset": 35190,
            "parents": [],
            "secId": "s0035",
            "sentence": "Approximately 98% of simulations and 99.5% of simulations resulted in costs per QALY gained by RZV versus No Vaccine below thresholds of $80,000 and $100,000, respectively.",
            "startOffset": 35018,
            "title": "Results"
        },
        {
            "endOffset": 39211,
            "parents": [],
            "secId": "s0040",
            "sentence": "The authors reported that the results were largely influenced by assumptions regarding duration of vaccine protection, inclusion of VE on PHN in patients who developed HZ, and a loss in quality of life associated with HZ and PHN.",
            "startOffset": 38982,
            "title": "Discussion"
        },
        {
            "endOffset": 20817,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 20816,
                    "startOffset": 20813
                }
            },
            "secId": "s0005",
            "sentence": "The VZV-specific cellular immunity declines with aging, and the VZV can reactivate in later life to cause HZ [2].",
            "startOffset": 20704,
            "title": "Introduction"
        },
        {
            "endOffset": 29895,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "These are described in detail in the supplementary text.",
            "startOffset": 29839,
            "title": "Model inputs"
        },
        {
            "endOffset": 33460,
            "parents": [],
            "secId": "s0035",
            "sentence": "These outcomes equate to a net cost of $11,863 per QALY gained.",
            "startOffset": 33397,
            "title": "Results"
        },
        {
            "endOffset": 28861,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0075": {
                    "endOffset": 28860,
                    "startOffset": 28853
                },
                "b0085": {
                    "endOffset": 28860,
                    "startOffset": 28853
                }
            },
            "secId": "s0025",
            "sentence": "The VE of RZV against HZ and PHN was taken from the ZOE-50 and ZOE-70 studies [15,17].",
            "startOffset": 28775,
            "title": "Model inputs"
        },
        {
            "endOffset": 26625,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Table 1 presents the epidemiological inputs applied in the base-case, sensitivity, and scenario analyses.",
            "startOffset": 26520,
            "title": "Model inputs"
        },
        {
            "endOffset": 30778,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0140": {
                    "endOffset": 30777,
                    "startOffset": 30773
                }
            },
            "secId": "s0025",
            "sentence": "Baseline utility values for the US population were taken from Szende et al. [28].",
            "startOffset": 30697,
            "title": "Model inputs"
        },
        {
            "endOffset": 34036,
            "parents": [],
            "secId": "s0035",
            "sentence": "The incremental vaccination costs would total almost $78 million dollars, but the HZ cases prevented would save $138 million in direct costs and over $35 million in indirect costs, resulting in net total societal cost savings of vaccinating that cohort of 1 million adults with RZV of approximately $96 million.",
            "startOffset": 33725,
            "title": "Results"
        },
        {
            "endOffset": 23282,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 23281,
                    "startOffset": 23277
                }
            },
            "secId": "s0005",
            "sentence": "The ACIP members subsequently recommended RZV vaccination: (1) in immunocompetent adults aged 50+ YOA, (2) in immunocompetent adults previously vaccinated with ZVL, and (3) preferred over ZVL [19].",
            "startOffset": 23085,
            "title": "Introduction"
        },
        {
            "endOffset": 30878,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0145": {
                    "endOffset": 30877,
                    "startOffset": 30873
                }
            },
            "secId": "s0025",
            "sentence": "QALY loss per HZ case by vaccination status and PHN status were reported in Pellissier et al. [29].",
            "startOffset": 30779,
            "title": "Model inputs"
        },
        {
            "endOffset": 29369,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "In the absence of long-term VE data, we assumed that the VE for 1-dose of RZV against both HZ and PHN waned at the same rate as the VE of ZVL.",
            "startOffset": 29227,
            "title": "Model inputs"
        },
        {
            "endOffset": 44786,
            "parents": [],
            "secId": "s0045",
            "sentence": "Shingrix is a trademark from the GSK group of companies.",
            "startOffset": 44730,
            "title": "Trademark section"
        },
        {
            "endOffset": 24639,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The ZOster ecoNomic Analysis (ZONA) model was developed in Microsoft Excel.",
            "startOffset": 24564,
            "title": "Mathematical model"
        },
        {
            "endOffset": 36975,
            "parents": [],
            "secId": "s0035",
            "sentence": "The model estimated that the QALY loss inputs could be 60% and 80% lower than the base-case and still result in an ICER of RZV versus No Vaccine less than a threshold of $50,000 and $100,000 per QALY, respectively.",
            "startOffset": 36761,
            "title": "Results"
        },
        {
            "endOffset": 45702,
            "parents": [],
            "secId": "s0050",
            "sentence": "The work presented in the article has been carried out in an ethical way.",
            "startOffset": 45629,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 23728,
            "parents": [],
            "secId": "s0005",
            "sentence": "The cost-effectiveness analysis was carried out comparing RZV versus No Vaccine, as well as the HZ vaccine standard of care strategy in 2017 (i.e. versus ZVL).",
            "startOffset": 23569,
            "title": "Introduction"
        },
        {
            "endOffset": 29838,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The model also takes into account the incidence of adverse events (AEs) and medically attended visits which are potentially related to vaccination.",
            "startOffset": 29691,
            "title": "Model inputs"
        },
        {
            "endOffset": 34781,
            "parents": [],
            "secId": "s0035",
            "sentence": "The highest ICER (or least cost-effective value) was observed when the annual waning of VE for RZV was at its upper bound ($63,858 per QALY gained).",
            "startOffset": 34633,
            "title": "Results"
        },
        {
            "endOffset": 28107,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Supplementary Text Table 2 presents the overall vaccine efficacy (VE) against HZ and PHN for both ZVL and RZV.",
            "startOffset": 27997,
            "title": "Model inputs"
        },
        {
            "endOffset": 43962,
            "parents": [],
            "secId": "s0040",
            "sentence": "The second-dose compliance was allowed to vary in DSA, PSA, and scenario analyses, which consistently showed that this parameter had little impact on the overall ICER.",
            "startOffset": 43795,
            "title": "Discussion"
        },
        {
            "endOffset": 39661,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 39660,
                    "startOffset": 39647
                },
                "b0120": {
                    "endOffset": 39660,
                    "startOffset": 39647
                },
                "b0160": {
                    "endOffset": 39660,
                    "startOffset": 39647
                },
                "b0165": {
                    "endOffset": 39660,
                    "startOffset": 39647
                }
            },
            "secId": "s0040",
            "sentence": "More recent analyses of cost-effectiveness of ZVL assumed waning of vaccine protection against HZ based on data from the Long Term Persistence Study [13,24,32,33].",
            "startOffset": 39498,
            "title": "Discussion"
        },
        {
            "endOffset": 44314,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 44313,
                    "startOffset": 44306
                },
                "b0085": {
                    "endOffset": 44313,
                    "startOffset": 44306
                }
            },
            "secId": "s0040",
            "sentence": "Vaccination against HZ with RZV has been demonstrated to be efficacious in two randomized phase III clinical trials [15,17].",
            "startOffset": 44190,
            "title": "Discussion"
        },
        {
            "endOffset": 23568,
            "parents": [],
            "secId": "s0005",
            "sentence": "The analysis was conducted to address the primary research questions: \u201cIs RZV cost-effective in US adults aged 60+ YOA who have never been vaccinated against HZ?\u201d",
            "startOffset": 23406,
            "title": "Introduction"
        },
        {
            "endOffset": 35450,
            "parents": [],
            "secId": "s0035",
            "sentence": "The results of the PSA for the RZV versus No Vaccine analysis are presented in Fig. 2 and Supplementary Text Fig. 3.",
            "startOffset": 35334,
            "title": "Results"
        },
        {
            "endOffset": 40016,
            "parents": [],
            "secId": "s0040",
            "sentence": "The DSA results in this paper also suggested that the cost-effectiveness of RZV versus No Vaccine was sensitive to assumptions regarding the waning of efficacy, in particular for waning of RZV 2-dose efficacy for subjects aged 70+ YOA.",
            "startOffset": 39781,
            "title": "Discussion"
        },
        {
            "endOffset": 30697,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "A weighted cost of AEs related to vaccine administration for both RZV and ZVL was included in the model.",
            "startOffset": 30593,
            "title": "Model inputs"
        },
        {
            "endOffset": 32397,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "We also conducted an analysis presenting the ICER for the health sector perspective for the base-case age group including adults aged 60+ YOA, comparing RZV with No Vaccine.",
            "startOffset": 32224,
            "title": "Sensitivity and scenario analyses"
        },
        {
            "endOffset": 36760,
            "parents": [],
            "secId": "s0035",
            "sentence": "ICERs were less sensitive to changes in the weighted AE cost per RZV dose from base estimates; as a result, ICERs stayed below a $100,000 threshold until costs were almost 7 times higher (582% increase) than base values.",
            "startOffset": 36540,
            "title": "Results"
        },
        {
            "endOffset": 38047,
            "parents": [],
            "secId": "s0035",
            "sentence": "Vaccinating with RZV at age 60 YOA would lead to cost savings while vaccinating at age 50 would yield an ICER of $14,916, compared with $4594, $20,383 and $56,143 at the ages 65, 70 and 80 YOA, respectively.",
            "startOffset": 37840,
            "title": "Results"
        },
        {
            "endOffset": 41332,
            "parents": [],
            "secId": "s0040",
            "sentence": "These values were extrapolated as inputs in the model.",
            "startOffset": 41278,
            "title": "Discussion"
        },
        {
            "endOffset": 40901,
            "parents": [],
            "secId": "s0040",
            "sentence": "The design of the ZOE studies was very close to the SPS study.",
            "startOffset": 40839,
            "title": "Discussion"
        },
        {
            "endOffset": 45462,
            "parents": [],
            "secId": "s0050",
            "sentence": "All named authors provided substantial intellectual and scientific input during the manuscript development, critically reviewing the content, revising the manuscript and giving final approval before submission.",
            "startOffset": 45252,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 21533,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 21532,
                    "startOffset": 21529
                }
            },
            "secId": "s0005",
            "sentence": "In the United States (US), 99.5% of the population 40+ years of age (YOA) have been infected with wild type VZV and are thus at risk of developing HZ [9].",
            "startOffset": 21379,
            "title": "Introduction"
        },
        {
            "endOffset": 45628,
            "parents": [],
            "secId": "s0050",
            "sentence": "The work described was carried out in accordance with the ICMJE recommendations for conducting, reporting, editing and publishing scholarly work in medical journals.",
            "startOffset": 45463,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 28774,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "In the model, both the HZ and PHN year 1 VE estimates are based on adjusted overall study VE, i.e. the overall VE estimates, which were estimated over \u22653 years, are adjusted upwards to take into account the waning during the clinical trial follow-up period.",
            "startOffset": 28517,
            "title": "Model inputs"
        },
        {
            "endOffset": 26103,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Further details are provided in the supplementary material text.",
            "startOffset": 26039,
            "title": "Model inputs"
        },
        {
            "endOffset": 28917,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Further details are provided in the Supplementary text.",
            "startOffset": 28862,
            "title": "Model inputs"
        },
        {
            "endOffset": 37839,
            "parents": [],
            "secId": "s0035",
            "sentence": "The model demonstrated that vaccinating with RZV was cost effective compared to No Vaccine for all ages investigated (i.e. 50, 60, 65, 70 and 80 YOA).",
            "startOffset": 37689,
            "title": "Results"
        },
        {
            "endOffset": 30042,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The model also takes into account the incidence of adverse events (AEs) and medically attended visits which are potentially related to vaccination.",
            "startOffset": 29895,
            "title": "Model inputs"
        },
        {
            "endOffset": 21182,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 21181,
                    "startOffset": 21176
                },
                "b0025": {
                    "endOffset": 21181,
                    "startOffset": 21176
                },
                "b0030": {
                    "endOffset": 21181,
                    "startOffset": 21176
                }
            },
            "secId": "s0005",
            "sentence": "Other less frequent complications of HZ include ocular, neurological, and cutaneous complications [4\u20136].",
            "startOffset": 21078,
            "title": "Introduction"
        },
        {
            "endOffset": 22152,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 22151,
                    "startOffset": 22147
                }
            },
            "secId": "s0005",
            "sentence": "Zostavax (Zoster Vaccine Live [ZVL]) is currently approved for the prevention of HZ in individuals 50+ YOA [14].",
            "startOffset": 22040,
            "title": "Introduction"
        },
        {
            "endOffset": 32223,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "In the second set, the ages targeted by the vaccine were changed to include adults aged 50+ YOA and then adults aged 65+ YOA.",
            "startOffset": 32098,
            "title": "Sensitivity and scenario analyses"
        },
        {
            "endOffset": 38202,
            "parents": [],
            "secId": "s0040",
            "sentence": "In this study we presented the cost-effectiveness of RZV compared to either No Vaccine or ZVL for vaccinating US adults aged 60+ YOA against HZ.",
            "startOffset": 38058,
            "title": "Discussion"
        },
        {
            "endOffset": 25371,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0100": {
                    "endOffset": 25370,
                    "startOffset": 25366
                }
            },
            "secId": "s0015",
            "sentence": "Further details regarding the model structure are provided in the Supplementary Text and elsewhere [20].",
            "startOffset": 25267,
            "title": "Mathematical model"
        },
        {
            "endOffset": 31134,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "A deterministic sensitivity analysis (DSA) was conducted.",
            "startOffset": 31077,
            "title": "Sensitivity and scenario analyses"
        },
        {
            "endOffset": 33724,
            "parents": [],
            "secId": "s0035",
            "sentence": "This reduced disease burden would result in a gain of 62 discounted life-years and 1261 discounted QALYs.",
            "startOffset": 33619,
            "title": "Results"
        },
        {
            "endOffset": 40666,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 40665,
                    "startOffset": 40658
                },
                "b0175": {
                    "endOffset": 40665,
                    "startOffset": 40658
                }
            },
            "secId": "s0040",
            "sentence": "The authors concluded that their assumptions were conservative, as did Najafzadeh [35], who reported that Le and Rothberg [34] used \u201ca conservative assumption that the RZV efficacy rate declines as fast as ZVL efficacy did, which is likely a cautious assumption\u201d [34,35].",
            "startOffset": 40395,
            "title": "Discussion"
        },
        {
            "endOffset": 42283,
            "parents": [],
            "refoffsets": {
                "b0185": {
                    "endOffset": 42282,
                    "startOffset": 42278
                }
            },
            "secId": "s0040",
            "sentence": "Nevertheless, phase II clinical trial data suggest that the immune responses after a single-dose administration remain above the pre-vaccination baseline throughout month 36 [37].",
            "startOffset": 42104,
            "title": "Discussion"
        },
        {
            "endOffset": 42795,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 42794,
                    "startOffset": 42790
                }
            },
            "secId": "s0040",
            "sentence": "Utility losses for HZ cases were based on data for ZVL [29].",
            "startOffset": 42735,
            "title": "Discussion"
        },
        {
            "endOffset": 25780,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The primary perspective is that of the societal perspective, which includes both direct medical costs and indirect costs.",
            "startOffset": 25659,
            "title": "Methodological assumptions"
        },
        {
            "endOffset": 35017,
            "parents": [],
            "secId": "s0035",
            "sentence": "The results of the PSA for the RZV versus No Vaccine analysis are presented in Fig. 2 and Supplementary Text Fig. 3.",
            "startOffset": 34901,
            "title": "Results"
        },
        {
            "endOffset": 31792,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Threshold analyses were conducted to investigate, for a selected set of key inputs, the values that those inputs could hold and still maintain ICER of RZV vs. No Vaccine below various willingness-to-pay hypothetical thresholds ranging from $0 to $160,000 per QALY gained.",
            "startOffset": 31521,
            "title": "Sensitivity and scenario analyses"
        },
        {
            "endOffset": 36539,
            "parents": [],
            "secId": "s0035",
            "sentence": "This analysis also showed that while waning of RZV efficacy remained lower than 1.5 and 2 times as much as the base-case estimates, the ICER did not exceed $50,000 and $100,000, respectively.",
            "startOffset": 36348,
            "title": "Results"
        },
        {
            "endOffset": 33014,
            "parents": [],
            "secId": "s0035",
            "sentence": "This corresponds to approximately a 50% reduction in these outcomes.",
            "startOffset": 32946,
            "title": "Results"
        },
        {
            "endOffset": 21635,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 21634,
                    "startOffset": 21631
                }
            },
            "secId": "s0005",
            "sentence": "It is estimated that, without an HZ vaccine, 30% of people will develop HZ during their lifetime [9].",
            "startOffset": 21534,
            "title": "Introduction"
        },
        {
            "endOffset": 43261,
            "parents": [],
            "refoffsets": {
                "b0190": {
                    "endOffset": 43173,
                    "startOffset": 43169
                }
            },
            "secId": "s0040",
            "sentence": "Similar findings of reduced disease severity of breakthrough HZ episodes in subjects vaccinated with RZV were reported for the ZOE-50 and ZOE-70 trial analyses [38], suggesting that the use of the same utility values is reasonable for both HZ vaccines.",
            "startOffset": 43009,
            "title": "Discussion"
        },
        {
            "endOffset": 44840,
            "parents": [],
            "secId": "s0045",
            "sentence": "Zostavax is a trademark from Merck Sharp & Dohme Corp.",
            "startOffset": 44786,
            "title": "Trademark section"
        },
        {
            "endOffset": 26735,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Supplementary text table 2 presents the overall vaccine efficacy (VE) against HZ and PHN for both ZVL and RZV.",
            "startOffset": 26625,
            "title": "Model inputs"
        },
        {
            "endOffset": 40264,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 40263,
                    "startOffset": 40259
                }
            },
            "secId": "s0040",
            "sentence": "Dooling et al. [19], when describing the waning rates of both vaccines, reported that vaccine effectiveness for ZVL \u201cwanes substantially over time\u201d whereas for RZV \u201cmodest waning of protection over 4 years following vaccination\u201d was observed [19].",
            "startOffset": 40017,
            "title": "Discussion"
        },
        {
            "endOffset": 25150,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The model follows all subjects within a cohort over their remaining lifetimes from the year of vaccination with annual cycle lengths.",
            "startOffset": 25017,
            "title": "Mathematical model"
        },
        {
            "endOffset": 38730,
            "parents": [],
            "secId": "s0040",
            "sentence": "Some differences existed in terms of waning inputs, as described below, and QALY inputs, i.e. the ZONA model assumed smaller QALY (utility) loss input values compared to the other models.",
            "startOffset": 38543,
            "title": "Discussion"
        },
        {
            "endOffset": 40838,
            "parents": [],
            "secId": "s0040",
            "sentence": "In the ZONA model, efficacy and waning assumptions, based on clinical trial data, for both HZ vaccines were validated by a panel of international experts in September 2016.",
            "startOffset": 40666,
            "title": "Discussion"
        },
        {
            "endOffset": 27144,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Waning of VE for ZVL against HZ was estimated to be 5.4% per year during the first 4 years following vaccination and 5.1% thereafter.",
            "startOffset": 27011,
            "title": "Model inputs"
        },
        {
            "endOffset": 37509,
            "parents": [],
            "secId": "s0035",
            "sentence": "In the second set of scenario analyses, comparing RZV versus No Vaccine for vaccinating US adults aged 50+ YOA and 65+ YOA, the model estimated ICERs of $12,617 and $22,616 per QALY gained, respectively.",
            "startOffset": 37306,
            "title": "Results"
        },
        {
            "endOffset": 39497,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 39393,
                    "startOffset": 39389
                },
                "b0155": {
                    "endOffset": 39496,
                    "startOffset": 39492
                }
            },
            "secId": "s0040",
            "sentence": "While Pellisier et al. [29] assumed no waning of VE in the base case analysis, Rothberg assumed a logarithmic waning function [31].",
            "startOffset": 39366,
            "title": "Discussion"
        },
        {
            "endOffset": 23084,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 23083,
                    "startOffset": 23079
                }
            },
            "secId": "s0005",
            "sentence": "In 2017, RZV was approved in the US by the FDA [18].",
            "startOffset": 23032,
            "title": "Introduction"
        },
        {
            "endOffset": 30099,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "These are described in detail in the Supplementary Text.",
            "startOffset": 30043,
            "title": "Model inputs"
        },
        {
            "endOffset": 41797,
            "parents": [],
            "secId": "s0040",
            "sentence": "Although both cell-mediated immunity and humoral immune responses to RZV decreased initially over time, both levelled off at around 4 years post-vaccination and remained stable, well above baseline, for 9 years in adults 60+ YOA.",
            "startOffset": 41568,
            "title": "Discussion"
        },
        {
            "endOffset": 25858,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Costs and outcomes are presented over the remaining lifetimes of individuals.",
            "startOffset": 25781,
            "title": "Methodological assumptions"
        },
        {
            "endOffset": 24459,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Three different HZ vaccination strategies are compared: No Vaccine, vaccination with ZVL, and vaccination with RZV.",
            "startOffset": 24344,
            "title": "Mathematical model"
        }
    ],
    "docId": "S0264410X18309356",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "desmond.x.curran@gsk.com",
                "first": "D.",
                "initial": "D.",
                "last": "Curran"
            },
            {
                "email": "brandon.j.patterson@gsk.com",
                "first": "B.",
                "initial": "B.",
                "last": "Patterson"
            },
            {
                "email": "lijoy.x.varghese@gsk.com",
                "first": "L.",
                "initial": "L.",
                "last": "Varghese"
            },
            {
                "email": "desiree.x.van-oorschot@gsk.com",
                "first": "D.",
                "initial": "D.",
                "last": "Van Oorschot"
            },
            {
                "email": "philip.o.buck@gsk.com",
                "first": "P.",
                "initial": "P.",
                "last": "Buck"
            },
            {
                "email": "jcarrico@rti.org",
                "first": "J.",
                "initial": "J.",
                "last": "Carrico"
            },
            {
                "email": "khicks@rti.org",
                "first": "K.",
                "initial": "K.",
                "last": "Hicks"
            },
            {
                "email": "brucelee@jhu.edu",
                "first": "B.",
                "initial": "B.",
                "last": "Lee"
            },
            {
                "email": "byawn47@gmail.com",
                "first": "B.",
                "initial": "B.",
                "last": "Yawn"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.07.005",
        "firstpage": "5037",
        "issn": "0264410X",
        "keywords": [
            "Cost-effectiveness",
            "Herpes zoster",
            "Public health impact",
            "Vaccination",
            "Vaccine"
        ],
        "lastpage": "5045",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States"
    }
}